

# Paul H Sugarbaker, Facs, Frcs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3559757/publications.pdf>

Version: 2024-02-01

296  
papers

16,042  
citations

23500

58  
h-index

19136

118  
g-index

301  
all docs

301  
docs citations

301  
times ranked

6114  
citing authors

#	ARTICLE	IF	CITATIONS
1	Peritonectomy Procedures. <i>Annals of Surgery</i> , 1995, 221, 29-42.	2.1	1,321
2	Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. <i>Cancer Treatment and Research</i> , 1996, 82, 359-374.	0.2	1,238
3	Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 2449-2456.	0.8	873
4	New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?. <i>Lancet Oncology</i> , The, 2006, 7, 69-76.	5.1	592
5	A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia. <i>American Journal of Surgical Pathology</i> , 2016, 40, 14-26.	2.1	528
6	Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy. <i>Annals of Surgery</i> , 1995, 221, 124-132.	2.1	509
7	Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. <i>Cancer</i> , 2001, 92, 85-91.	2.0	332
8	A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2007, 14, 2702-2713.	0.7	321
9	Successful management of microscopic residual disease in large bowel cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, S15-S25.	1.1	310
10	A Systematic Review on the Efficacy of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei. <i>Annals of Surgical Oncology</i> , 2007, 14, 484-492.	0.7	268
11	Analysis of Prognostic Factors in Seventy Patients Having a Complete Cytoreduction plus Perioperative Intraperitoneal Chemotherapy for Carcinomatosis from Colorectal Cancer. <i>Journal of the American College of Surgeons</i> , 2006, 203, 878-886.	0.2	258
12	Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. <i>International Seminars in Surgical Oncology</i> , 2005, 2, 3.	1.1	248
13	A review of peritoneal mesothelioma at the Washington Cancer Institute. <i>Surgical Oncology Clinics of North America</i> , 2003, 12, 605-621.	0.6	247
14	Hepatic Resection of Coirectal Metastases. <i>Annals of Surgery</i> , 1985, 201, 210-218.	2.1	240
15	Evaluation of computed tomography in patients with peritoneal carcinomatosis. <i>Cancer</i> , 1993, 72, 1631-1636.	2.0	240
16	Prospective Morbidity and Mortality Assessment of Cytoreductive Surgery Plus Perioperative Intraperitoneal Chemotherapy To Treat Peritoneal Dissemination of Appendiceal Mucinous Malignancy. <i>Annals of Surgical Oncology</i> , 2006, 13, 635-644.	0.7	240
17	Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. , 1996, 77, 2622-2629.		215
18	Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. <i>Cancer and Metastasis Reviews</i> , 2003, 22, 465-472.	2.7	199

#	ARTICLE	IF	CITATIONS
19	Bologna guidelines for diagnosis and management of adhesive small bowel obstruction (ASBO): 2013 update of the evidence-based guidelines from the world society of emergency surgery ASBO working group. <i>World Journal of Emergency Surgery</i> , 2013, 8, 42.	2.1	197
20	Update on Chemotherapeutic Agents Utilized for Perioperative Intraperitoneal Chemotherapy. <i>Oncologist</i> , 2005, 10, 112-122.	1.9	163
21	Thermal Enhancement of New Chemotherapeutic Agents at Moderate Hyperthermia. <i>Annals of Surgical Oncology</i> , 2003, 10, 463-468.	0.7	158
22	Peritonectomy procedures. <i>Surgical Oncology Clinics of North America</i> , 2003, 12, 703-727.	0.6	152
23	Malignant pseudomyxoma peritonei of colonic origin. <i>Diseases of the Colon and Rectum</i> , 1987, 30, 772-779.	0.7	151
24	Clinical Pathway for the Management of Resectable Gastric Cancer with Peritoneal Seeding: Best Palliation with a Ray of Hope for Cure. <i>Oncology</i> , 2000, 58, 96-107.	0.9	150
25	Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. <i>Cancer</i> , 2005, 103, 839-849.	2.0	147
26	Malignant transformation of "benign" cystic mesothelioma of the peritoneum. <i>Journal of Surgical Oncology</i> , 2002, 79, 243-251.	0.8	146
27	Peritoneal Carcinomatosis from Adenocarcinoma of the Colon. <i>World Journal of Surgery</i> , 1996, 20, 585-592.	0.8	140
28	Indications for Early Postoperative Intraperitoneal Chemotherapy of Advanced Gastric Cancer: Results of a Prospective Randomized Trial. <i>World Journal of Surgery</i> , 2001, 25, 985-990.	0.8	137
29	Epithelial Appendiceal Neoplasms. <i>Cancer Journal (Sudbury, Mass )</i> , 2009, 15, 225-235.	1.0	136
30	Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach?. <i>Lancet Oncology</i> , The, 2012, 13, e362-e369.	5.1	135
31	Second-look Surgery after Cytoreduction and Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer: Analysis of Prognostic Features. <i>World Journal of Surgery</i> , 1999, 23, 23-29.	0.8	134
32	Influence of surgical techniques on survival in patients with colorectal cancer. <i>Diseases of the Colon and Rectum</i> , 1982, 25, 545-557.	0.7	132
33	Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 41, 147-154.	1.1	127
34	Critical Analysis of Treatment Failure After Complete Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Peritoneal Dissemination From Appendiceal Mucinous Neoplasms. <i>Annals of Surgical Oncology</i> , 2007, 14, 2289-2299.	0.7	122
35	Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma. <i>Annals of Surgical Oncology</i> , 2006, 14, 41-49.	0.7	116
36	Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. <i>Journal of Surgical Oncology</i> , 2004, 87, 162-166.	0.8	111

#	ARTICLE	IF	CITATIONS
37	Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: The evolution of treatment strategies for advanced gastric cancer. <i>Journal of Surgical Oncology</i> , 2003, 21, 233-248.	1.4	109
38	The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). <i>European Journal of Surgical Oncology</i> , 2018, 44, 1942-1948.	0.5	107
39	Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C. <i>Annals of Surgical Oncology</i> , 2002, 9, 186-191.	0.7	95
40	Peritoneum as the first-line of defense in carcinomatosis. <i>Journal of Surgical Oncology</i> , 2007, 95, 93-96.	0.8	93
41	Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. <i>Journal of Surgical Oncology</i> , 2010, 102, 576-581.	0.8	84
42	Histopathologic Analysis in 46 Patients with Pseudomyxoma Peritonei Syndrome: Failure versus Success with a Second-Look Operation. <i>Modern Pathology</i> , 2001, 14, 164-171.	2.9	81
43	Pharmacokinetics and Pharmacodynamics of Perioperative Cancer Chemotherapy in Peritoneal Surface Malignancy. <i>Cancer Journal (Sudbury, Mass )</i> , 2009, 15, 216-224.	1.0	81
44	Failure Analysis of Recurrent Disease Following Complete Cytoreduction and Perioperative Intraperitoneal Chemotherapy in Patients with Peritoneal Carcinomatosis from Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2007, 14, 2281-2288.	0.7	78
45	Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin c in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix. <i>Cancer</i> , 1990, 65, 1495-1501.	2.0	77
46	Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 108-112.	1.1	75
47	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: Progress toward a new standard of care. <i>Cancer Treatment Reviews</i> , 2016, 48, 42-49.	3.4	73
48	Pleural extension of mucinous tumor in patients with pseudomyxoma peritonei syndrome. <i>Annals of Surgical Oncology</i> , 2000, 7, 199-203.	0.7	72
49	Clinical Presentation of Peritoneal Mesothelioma. <i>Tumori</i> , 2003, 89, 269-273.	0.6	72
50	Pharmacokinetics of intraperitoneal oxaliplatin: Experimental studies. <i>Journal of Surgical Oncology</i> , 2001, 76, 106-114.	0.8	68
51	Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 703-708.	1.1	68
52	Systemic Chemotherapy prior to Cytoreductive Surgery and HIPEC for Carcinomatosis from Appendix Cancer: Impact on Perioperative Outcomes and Short-Term Survival. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-6.	0.7	68
53	Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI). <i>International Journal of Hyperthermia</i> , 2017, 33, 520-527.	1.1	68
54	Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 29-44.	0.6	68

#	ARTICLE	IF	CITATIONS
55	Morbidity and Mortality Assessment of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma—A Prospective Study of 70 Consecutive Cases. <i>Annals of Surgical Oncology</i> , 2007, 14, 515-525.	0.7	67
56	Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 9286-91.	1.4	66
57	Peritoneal Cystic Mesothelioma: A Case Series. <i>Tumori</i> , 2003, 89, 31-35.	0.6	65
58	Surgical responsibilities in the management of peritoneal carcinomatosis. <i>Journal of Surgical Oncology</i> , 2010, 101, 713-724.	0.8	64
59	Peritonectomy Procedures. , 2007, 134, 247-264.		60
60	Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 405-410.	1.1	58
61	Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. <i>Journal of Surgical Oncology</i> , 2008, 98, 295-299.	0.8	58
62	A simplified approach to hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) using a self retaining retractor. <i>Cancer Treatment and Research</i> , 1996, 82, 415-421.	0.2	56
63	Dissection by electrocautery with a ball tip. <i>Journal of Surgical Oncology</i> , 1994, 56, 246-248.	0.8	55
64	Metastatic inefficiency: The scientific basis for resection of liver metastases from colorectal cancer. <i>Journal of Surgical Oncology</i> , 1993, 53, 158-160.	0.8	54
65	Peritoneal mesothelioma. <i>Current Treatment Options in Oncology</i> , 2002, 3, 375-386.	1.3	54
66	Intraperitoneal taxanes. <i>Surgical Oncology Clinics of North America</i> , 2003, 12, 825-833.	0.6	52
67	Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 147-156.	1.1	52
68	Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. <i>International Journal of Hyperthermia</i> , 2017, 33, 582-592.	1.1	51
69	Management of Malignant Peritoneal Mesothelioma Using Cytoreductive Surgery and Perioperative Chemotherapy. <i>Journal of Oncology Practice</i> , 2016, 12, 928-935.	2.5	50
70	Update on the management of malignant peritoneal mesothelioma. <i>Translational Lung Cancer Research</i> , 2018, 7, 599-608.	1.3	50
71	Peritonectomy procedures. <i>Cancer Treatment and Research</i> , 1996, 82, 235-253.	0.2	50
72	Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 19.	0.8	48

#	ARTICLE	IF	CITATIONS
73	Mucinous colorectal carcinoma. <i>Journal of Surgical Oncology</i> , 2001, 77, 282-283.	0.8	47
74	Clinicopathologic and Prognostic Features in Patients with Peritoneal Metastasis from Mucinous Adenocarcinoma, Adenocarcinoma with Signet Ring Cells, and Adenocarcinoid of the Appendix Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 1474-1480.	0.7	46
75	Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1965-1977.	0.9	45
76	Pharmacokinetics of Intraperitoneal Gemcitabine in a Rat Model. <i>Tumori</i> , 1998, 84, 706-711.	0.6	44
77	Current status and future prospects of clinical trials on CRS+HIPEC for gastric cancer peritoneal metastases. <i>International Journal of Hyperthermia</i> , 2017, 33, 562-570.	1.1	43
78	Clinically aggressive pseudomyxoma peritonei: A variant of a histologically indolent process. <i>Journal of Surgical Oncology</i> , 2004, 86, 10-15.	0.8	42
79	Effect of intraperitoneal chemotherapy and fibrinolytic therapy on tumor implantation in wound sites. , 1996, 62, 128-134.		40
80	Major amputations done with palliative intent in the treatment of local bony complications associated with advanced cancer. <i>Journal of Surgical Oncology</i> , 1991, 47, 121-130.	0.8	39
81	Pharmacology of Perioperative Intraperitoneal and Intravenous Chemotherapy in Patients with Peritoneal Surface Malignancy. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 577-597.	0.6	39
82	Surgical Management of Carcinomatosis from Colorectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2005, 18, 190-203.	0.5	38
83	A perspective on clinical research strategies in carcinoma of the large bowel. <i>World Journal of Surgery</i> , 1991, 15, 609-616.	0.8	37
84	Concerning CT features used to select patients for treatment of peritoneal metastases, a pictorial essay. <i>International Journal of Hyperthermia</i> , 2017, 33, 497-504.	1.1	37
85	Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin. <i>European Journal of Surgical Oncology</i> , 2021, 47, 738-742.	0.5	37
86	Prevention and Treatment of Peritoneal Metastases: a Comprehensive Review. <i>Indian Journal of Surgical Oncology</i> , 2019, 10, 3-23.	0.3	36
87	Rectovaginal fistula following low circular stapled anastomosis in women with rectal cancer. , 1996, 61, 155-158.		35
88	Docetaxel and hyperthermia: Factors that modify thermal enhancement. <i>Journal of Surgical Oncology</i> , 2004, 88, 14-20.	0.8	35
89	A Curative Approach to Peritoneal Carcinomatosis from Colorectal Cancer. <i>Seminars in Oncology</i> , 2005, 32, 68-73.	0.8	35
90	When and When Not to Perform a Right Colon Resection with Mucinous Appendiceal Neoplasms. <i>Annals of Surgical Oncology</i> , 2017, 24, 729-732.	0.7	35

#	ARTICLE	IF	CITATIONS
91	Pharmacology of perioperative 5-Fluorouracil. <i>Journal of Surgical Oncology</i> , 2010, 102, 730-735.	0.8	34
92	Prior Surgical Score: An Analysis of the Prognostic Significance of an Initial Nondefinitive Surgical Intervention in Patients With Peritoneal Carcinomatosis of a Colorectal Origin Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 347-354.	0.7	34
93	An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution. <i>Journal of Surgical Oncology</i> , 2005, 92, 142-146.	0.8	33
94	Hyperthermic Intraoperative Thoracoabdominal Chemotherapy. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-7.	0.7	33
95	Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution's Experience During Two Decades. <i>Annals of Surgical Oncology</i> , 2017, 24, 898-905.	0.7	33
96	Avoiding Diverting Ileostomy in Patients Requiring Complete Pelvic Peritonectomy. <i>Annals of Surgical Oncology</i> , 2016, 23, 1481-1485.	0.7	32
97	Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database. <i>Journal of Surgical Oncology</i> , 2007, 96, 102-112.	0.8	31
98	Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2009, 21, 15-24.	0.9	31
99	Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience. <i>Journal of Surgical Oncology</i> , 2019, 119, 336-346.	0.8	31
100	Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-5.	0.7	30
101	Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience. <i>Annals of Surgical Oncology</i> , 2018, 25, 1184-1192.	0.7	30
102	Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A New Standard of Care for Appendiceal Mucinous Tumors with Peritoneal Dissemination. <i>Clinics in Colon and Rectal Surgery</i> , 2005, 18, 204-214.	0.5	29
103	Management of Mucinous Urachal Neoplasm Presenting as Pseudomyxoma Peritonei. <i>Tumori</i> , 2008, 94, 732-736.	0.6	29
104	Improving oncologic outcomes for colorectal cancer at high risk for local/regional recurrence with novel surgical techniques. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 205-213.	1.4	29
105	Peritoneal Metastases from Gastrointestinal Cancer. <i>Current Oncology Reports</i> , 2018, 20, 62.	1.8	29
106	Third look surgery and beyond for appendiceal malignancy with peritoneal dissemination. <i>Journal of Surgical Oncology</i> , 2003, 83, 5-12.	0.8	28
107	Strategies for management of the peritoneal surface component of cancer: cytoreductive surgery plus perioperative intraperitoneal chemotherapy. <i>Journal of Oncology Pharmacy Practice</i> , 2005, 11, 111-119.	0.5	28
108	Second-Look Surgery for Colorectal Cancer: Revised Selection Factors and New Treatment Options for Greater Success. <i>International Journal of Surgical Oncology</i> , 2011, 2011, 1-8.	0.3	28

#	ARTICLE	IF	CITATIONS
109	Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus. <i>Annals of Surgical Oncology</i> , 2015, 22, 2799-2805.	0.7	28
110	Pharmacokinetic Study of Perioperative Intravenous Ifosfamide. <i>International Journal of Surgical Oncology</i> , 2011, 2011, 1-9.	0.3	26
111	Parietal Peritonectomy. <i>Annals of Surgical Oncology</i> , 2012, 19, 1250-1250.	0.7	26
112	The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). <i>European Journal of Surgical Oncology</i> , 2021, 47, 2888-2892.	0.5	26
113	Limited Survival in the Treatment of Carcinomatosis From Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 2258-2263.	0.7	25
114	Preoperative Assessment of Cancer Patients with Peritoneal Metastases for Complete Cytoreduction. <i>Indian Journal of Surgical Oncology</i> , 2016, 7, 295-302.	0.3	25
115	Cytoreductive Surgery and HIPEC as a Treatment Option for Laparoscopic Resection of Uterine Leiomyosarcoma with Morcellation: Early Results. <i>Annals of Surgical Oncology</i> , 2016, 23, 1501-1507.	0.7	25
116	Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice. <i>Pleura and Peritoneum</i> , 2017, 2, 63-72.	0.5	25
117	Early distant metastases from epithelioid sarcoma of the hand. <i>Cancer</i> , 1981, 48, 852-855.	2.0	24
118	Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: A multi-institutional cohort from PSOGI. <i>European Journal of Surgical Oncology</i> , 2021, 47, 172-180.	0.5	24
119	Transureteroureterostomy: an adjunct to the management of advanced primary and recurrent pelvic malignancy. <i>International Journal of Colorectal Disease</i> , 2003, 18, 40-44.	1.0	23
120	Total anterior parietal peritonectomy. <i>Journal of Surgical Oncology</i> , 2003, 83, 261-263.	0.8	23
121	Compartment syndrome of the leg associated with lithotomy position for cytoreductive surgery. <i>Journal of Surgical Oncology</i> , 2007, 96, 619-623.	0.8	23
122	Cytoreduction of the small bowel surfaces. <i>Journal of Surgical Oncology</i> , 2008, 97, 176-179.	0.8	23
123	Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer: Rationale and Report of Early Data. <i>International Journal of Surgical Oncology</i> , 2011, 2011, 1-7.	0.3	23
124	Pharmacokinetics of Hyperthermic Intrathoracic Chemotherapy following Pleurectomy and Decortication. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-4.	0.7	23
125	Radical appendectomy as an alternative to right colon resection in patients with epithelial appendiceal neoplasms. <i>Surgical Oncology</i> , 2017, 26, 86-90.	0.8	23
126	Body surface area-based vs concentration-based perioperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal surface malignancy treatment: COBOX trial. <i>Journal of Surgical Oncology</i> , 2019, 119, 999-1010.	0.8	23



#	ARTICLE	IF	CITATIONS
127	Pharmacokinetics of the intraperitoneal nanoparticle pegylated liposomal doxorubicin in patients with peritoneal metastases. <i>European Journal of Surgical Oncology</i> , 2021, 47, 108-114.	0.5	23
128	Managing the peritoneal surface component of gastrointestinal cancer. Part 2. Perioperative intraperitoneal chemotherapy. <i>Oncology</i> , 2004, 18, 207-19; discussion 220-2, 227-8, 230.	0.4	23
129	Neutropenia following Perioperative Intraperitoneal Chemotherapy. <i>Tumori</i> , 1999, 85, 41-46.	0.6	22
130	Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1786-1792.	0.5	22
131	Repeat hepatic resections for colorectal metastases. <i>British Journal of Surgery</i> , 2005, 77, 230-233.	0.1	19
132	Adjuvant Bidirectional Chemotherapy Using an Intraperitoneal Port. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-5.	0.7	19
133	Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 151-155.	1.1	18
134	Peritoneal Metastases, a Frontier for Progress. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 413-424.	0.6	18
135	Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: lessons learned from PRODIGE 7. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, S120-S128.	0.6	18
136	Congenital pleuroperitoneal communication in a patient with pseudomyxoma peritonei. , 2000, 73, 174-178.		17
137	The Porta Hepatis as a Site of Recurrence of Mucinous Appendiceal Neoplasms Treated by Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy. <i>Tumori</i> , 2008, 94, 694-700.	0.6	17
138	Evolution of Treatments for Peritoneal Metastases From Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2122-2123.	0.8	17
139	Prognostic factor analysis of circulating tumor cells in peripheral blood of patients with peritoneal carcinomatosis of colon cancer origin treated with cytoreductive surgery plus an intraoperative hyperthermic intraperitoneal chemotherapy procedure (CRS + HIPEC). <i>Surgery</i> , 2016, 159, 728-735.	1.0	17
140	Multi-institutional study of peritoneal sarcomatosis from uterine sarcoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2170-2177.	0.5	17
141	Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization. <i>Oncotarget</i> , 2019, 10, 1407-1424.	0.8	17
142	Mechanisms of relapse for colorectal cancer: Implications for intraperitoneal chemotherapy. <i>Journal of Surgical Oncology</i> , 1991, 48, 36-41.	0.8	16
143	Cholecystectomy, lesser omentectomy, and stripping of the omental bursa: A peritonectomy procedure. <i>Journal of Surgical Oncology</i> , 2003, 84, 45-49.	0.8	16
144	Pont hepatic (hepatic bridge), an important anatomic structure in cytoreductive surgery. <i>Journal of Surgical Oncology</i> , 2010, 101, 251-252.	0.8	16

#	ARTICLE	IF	CITATIONS
145	Early Intervention for Treatment and Prevention of Colorectal Carcinomatosis. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 689-703.	0.6	16
146	Strategies to improve local control of resected pancreas adenocarcinoma. <i>Surgical Oncology</i> , 2017, 26, 63-70.	0.8	16
147	Intraperitoneal paclitaxel: pharmacology, clinical results and future prospects. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, S231-S239.	0.6	16
148	Management of peritoneal metastases - Basic concepts. <i>Journal of B U on</i> , 2015, 20 Suppl 1, S2-11.	0.4	16
149	Carcinomatosis from gastrointestinal cancer. <i>Annals of Medicine</i> , 2004, 36, 9-22.	1.5	15
150	Discordant Histology of Primary Appendiceal Adenocarcinoid Neoplasms with Peritoneal Dissemination. <i>Annals of Surgical Oncology</i> , 2008, 15, 1440-1446.	0.7	15
151	Revised guidelines for second-look surgery in patients with colon and rectal cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 621-628.	1.2	15
152	Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients. <i>Annals of Surgical Oncology</i> , 2018, 25, 1094-1100.	0.7	14
153	Intraperitoneal delivery of chemotherapeutic agents for the treatment of peritoneal metastases: current challenges and how to overcome them. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 1393-1401.	2.4	14
154	Strategies for the prevention and treatment of peritoneal carcinomatosis from gastrointestinal cancer. <i>Cancer Investigation</i> , 2005, 23, 155-72.	0.6	14
155	Fluoroscopically Guided Peritoneal Catheter Placement for Intraperitoneal Chemotherapy. <i>Journal of Vascular and Interventional Radiology</i> , 1994, 5, 161-165.	0.2	13
156	Colorectal carcinomatosis: a new oncologic frontier. <i>Current Opinion in Oncology</i> , 2005, 17, 397-399.	1.1	13
157	Circumferential cutaneous traction for exposure of the layers of the abdominal wall. <i>Journal of Surgical Oncology</i> , 2008, 98, 472-475.	0.8	13
158	Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 4231-4237.	0.7	13
159	Managing the peritoneal surface component of gastrointestinal cancer. Part 1. Patterns of dissemination and treatment options. <i>Oncology</i> , 2004, 18, 51-9.	0.4	13
160	Peritoneal Carcinomatosis from an Unknown Primary Site. Management of 15 Patients. <i>Tumori</i> , 2001, 87, 67-73.	0.6	12
161	Decreasing the Risk of a Treatment Expands Its Indications. <i>Annals of Surgical Oncology</i> , 2005, 12, 868-870.	0.7	12
162	Building on a consensus. <i>Journal of Surgical Oncology</i> , 2008, 98, 215-216.	0.8	12

#	ARTICLE	IF	CITATIONS
163	Five Reasons Why Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Must be Regarded as the New Standard of Care for Diffuse Malignant Peritoneal. <i>Annals of Surgical Oncology</i> , 2010, 17, 1710-1712.	0.7	12
164	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial and recurrent ovarian carcinoma: a single center experience. <i>International Journal of Hyperthermia</i> , 2018, 34, 564-569.	1.1	12
165	Sclerosing encapsulating peritonitis as a potential complication of cytoreductive surgery and HIPEC: Clinical features and results of treatment in 4 patients. <i>Surgical Oncology</i> , 2018, 27, 657-662.	0.8	12
166	Port site metastases after minimally invasive resection for colorectal cancer: A retrospective study of 13 patients. <i>Surgical Oncology</i> , 2019, 29, 20-24.	0.8	12
167	Patient Selection for Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Cancer: Consensus on Decision Making Among International Experts. <i>Clinical Colorectal Cancer</i> , 2020, 19, 277-284.	1.0	12
168	Management of mucinous urachal neoplasm presenting as pseudomyxoma peritonei. <i>Tumori</i> , 2008, 94, 732-6.	0.6	12
169	Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer. <i>Journal of Surgical Oncology</i> , 2003, 83, 197-203.	0.8	11
170	The Seven Best from PSOGI 2016. <i>Annals of Surgical Oncology</i> , 2017, 24, 870-874.	0.7	11
171	The hepatic bridge. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1083-1086.	0.5	11
172	Cytoreductive Surgery Plus HIPEC With and Without NIPEC for Malignant Peritoneal Mesothelioma: A Propensity-Matched Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 7109-7117.	0.7	11
173	Extremity soft tissue sarcoma with metastases to abdominopelvic surfaces. , 1997, 64, 68-73.		10
174	Thin-Walled Cysts as a Pathognomonic CT Finding in Cystic Mesothelioma. <i>Tumori</i> , 2008, 94, 14-18.	0.6	10
175	Rectus Abdominis Muscle Resection for Abdominal Wall Recurrence of Mucinous Adenocarcinoma or Peritoneal Mesothelioma. <i>Tumori</i> , 2008, 94, 309-313.	0.6	10
176	Colorectal Cancer Metastases. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 289-298.	0.6	10
177	Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series. <i>Surgical Oncology</i> , 2020, 33, 96-99.	0.8	10
178	Concerning CT features predict outcome of treatment in patients with malignant peritoneal mesothelioma. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2212-2219.	0.5	10
179	The many faces of intraperitoneal chemotherapy. <i>Surgical Oncology</i> , 2022, 40, 101676.	0.8	10
180	Clinical Pathway for Peritoneal Carcinomatosis from Colon and Rectal Cancer: Guidelines for Current Practice. <i>Tumori</i> , 1997, 83, 725-728.	0.6	9

#	ARTICLE	IF	CITATIONS
181	Peritoneal metastases from mucinous endocervical adenocarcinoma. <i>Gynecologic Oncology Reports</i> , 2014, 10, 5-8.	0.3	9
182	The Initial Indian Experience with Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases. <i>Indian Journal of Surgical Oncology</i> , 2016, 7, 160-165.	0.3	9
183	A Prognostic Model for Predicting Overall Survival in Patients with Peritoneal Surface Malignancy of an Appendiceal Origin Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 2266-2272.	0.7	9
184	Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview. <i>Pleura and Peritoneum</i> , 2017, 2, 85-93.	0.5	9
185	Intraperitoneal gemcitabine chemotherapy is safe for patients with resected pancreatic cancer: final clinical and pharmacologic data from a phase II protocol and recommended future directions. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, S99-S109.	0.6	9
186	Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 719-724.	1.1	8
187	Gastric perforation following cytoreductive surgery with perioperative intraperitoneal chemotherapy. <i>Journal of Surgical Oncology</i> , 2010, 101, 634-636.	0.8	8
188	Long-term survival is possible using cytoreductive surgery plus HIPEC for sarcomatosisâ€”Case report of 2 patients. <i>International Journal of Surgery Case Reports</i> , 2019, 64, 10-14.	0.2	8
189	After thirty years of experience with early postoperative intraperitoneal 5-fluorouracil now saying goodbye. <i>Surgical Oncology</i> , 2022, 42, 101757.	0.8	8
190	A cytoreductive approach to treatment of multiple liver metastases. <i>Journal of Surgical Oncology</i> , 1993, 53, 161-165.	0.8	7
191	Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 477-487.	1.1	7
192	Comprehensive Management of Disseminated Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 3327-3330.	0.7	7
193	Peritoneal tunnels: A site at risk for treatment failure when performing treatments for peritoneal metastases. A case series of 2 patients. <i>International Journal of Surgery Case Reports</i> , 2019, 61, 309-312.	0.2	7
194	Decision-Making Analysis for Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: A Survey by the Executive Committee of the Peritoneal Surface Oncology Group International (PSOGI). <i>Oncology</i> , 2021, 99, 41-48.	0.9	7
195	Clinical Research to Standard of Care: When Does the Transition Occur?. <i>Annals of Surgical Oncology</i> , 2003, 10, 825-826.	0.7	6
196	Avoiding Carcinogen Exposure With Intraperitoneal Paclitaxel. <i>Oncology Nursing Forum</i> , 2005, 32, 44-48.	0.5	6
197	Reported Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Systemic Toxicity. <i>Annals of Surgical Oncology</i> , 2008, 15, 1800-1801.	0.7	6
198	Eradication of minimal residual disease in the perioperative period in primary colon cancer. <i>Colorectal Cancer</i> , 2015, 4, 157-166.	0.8	6

#	ARTICLE	IF	CITATIONS
199	Perioperative FOLFOX in management of peritoneal metastases of colorectal cancer. Case report of 2 patients. <i>International Journal of Surgery Case Reports</i> , 2020, 75, 279-285.	0.2	6
200	Synchronous primary neuroendocrine and mucinous epithelial tumors present in the same appendix. Case report of 2 patients. <i>International Journal of Surgery Case Reports</i> , 2020, 67, 76-79.	0.2	6
201	Prevention and Treatment of Peritoneal Metastases from Gastric Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 1899.	1.0	6
202	Treatment of advanced pseudomyxoma peritonei using cytoreductive surgery including total gastrectomy and perioperative chemotherapy. <i>Journal of Surgical Oncology</i> , 2021, 124, 378-389.	0.8	6
203	Peritoneal carcinomatosis of unknown primary site, a study of 25 patients over 30 years. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1908-1911.	0.5	6
204	Cytoreductive surgery and intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. , 2003, 5, 192-198.		6
205	Rectus abdominis muscle resection for abdominal wall recurrence of mucinous adenocarcinoma or peritoneal mesothelioma. <i>Tumori</i> , 2008, 94, 309-13.	0.6	6
206	An Evolving Role of Perioperative Intraperitoneal Chemotherapy After Cytoreductive Surgery for Colorectal Peritoneal Carcinomatosis. <i>Annals of Surgical Oncology</i> , 2007, 14, 2171-2172.	0.7	5
207	Advances in diffuse malignant peritoneal mesothelioma. <i>Oncology Reviews</i> , 2007, 1, 53-64.	0.8	5
208	Peritoneal Metastases: Prevention and Treatment. <i>Indian Journal of Surgical Oncology</i> , 2016, 7, 137-138.	0.3	5
209	Rectus abdominis muscle transplant for repair of abdominal wall defects required for cancer resections: Case report. <i>International Journal of Surgery Case Reports</i> , 2019, 62, 62-64.	0.2	5
210	Peritoneal cytology as an indicator of peritoneal metastases in colorectal cancer. <i>Journal of Surgical Oncology</i> , 2021, 124, 361-366.	0.8	5
211	Appendiceal tumors with glandular and neuroendocrine features exhibiting peritoneal metastases - Critical evaluation of outcome following cytoreductive surgery with perioperative chemotherapy. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1278-1285.	0.5	5
212	Effects of postoperative intraperitoneal chemotherapy on peritoneal wound healing and adhesion formation. <i>Cancer Treatment and Research</i> , 1996, 82, 327-335.	0.2	5
213	Cytoreductive Surgery and HIPEC in the Baltic States: An International Scientific Workshop with Live Surgery. <i>Viszeralmedizin</i> , 2014, 30, 353-359.	0.0	5
214	Anatomic sites of disease in colorectal cancer patients recorded at the time of cytoreductive surgery for peritoneal metastases. <i>European Journal of Surgical Oncology</i> , 2022, 48, 946-955.	0.5	5
215	Revised prognostic indicators for treatment of lymph node positive colorectal peritoneal metastases. <i>Journal of Surgical Oncology</i> , 2022, 125, 889-900.	0.8	5
216	Psoas/iliacus muscle invasion from mucinous appendiceal neoplasm. Radiologic appearance and outcome of treatment in 3 patients. <i>Surgical Oncology</i> , 2018, 27, 154-157.	0.8	4

#	ARTICLE	IF	CITATIONS
217	Ovarian metastases from right colon cancer treated with systemic cancer chemotherapy, a case report. <i>International Journal of Surgery Case Reports</i> , 2018, 47, 25-29.	0.2	4
218	Case report of combined surgical oncologic and bariatric procedures. <i>International Journal of Surgery Case Reports</i> , 2018, 50, 5-8.	0.2	4
219	Port site recurrence, an unintended consequence of laparoscopic resection of ovarian cancer. A case report. <i>International Journal of Surgery Case Reports</i> , 2019, 62, 5-8.	0.2	4
220	Peritoneal metastases from malignant degeneration of ectopic gastric epithelium in Meckel's diverticulum: A case report. <i>International Journal of Surgery Case Reports</i> , 2019, 61, 305-308.	0.2	4
221	Total pelvic exenterative surgery in patients with peritoneal metastases from appendiceal neoplasms. A case series of 2 patients. <i>International Journal of Surgery Case Reports</i> , 2019, 65, 279-283.	0.2	4
222	HIPEC plus EPIC paclitaxel for maximal perioperative treatments of advanced epithelial ovarian cancer. Long-term results of a pilot study. <i>Surgical Oncology</i> , 2020, 35, 441-446.	0.8	4
223	The PRODIGE 7 randomized trial has 4 design flaws and 4 pharmacologic flaws and cannot be used to discredit other HIPEC regimens. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, S129-S130.	0.6	4
224	Kocher maneuver to facilitate cytoreduction within the foramen of Winslow. <i>Journal of Surgical Oncology</i> , 2017, 115, 788-790.	0.8	4
225	The porta hepatis as a site of recurrence of mucinous appendiceal neoplasms treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. <i>Tumori</i> , 2008, 94, 694-700.	0.6	4
226	How safe and effective is surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2007, 4, 490-491.	1.7	3
227	Peritoneal Metastases from Adrenal Cortical Carcinoma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Tumori</i> , 2016, 102, 588-592.	0.6	3
228	Oligometastatic Disease in the Peritoneal Space with Gastrointestinal Cancer. <i>Visceral Medicine</i> , 2017, 33, 42-46.	0.5	3
229	Peritoneal carcinomatosis of unknown primary site may be an undiagnosed appendiceal adenocarcinoma. A case series. <i>International Journal of Surgery Case Reports</i> , 2019, 63, 65-68.	0.2	3
230	Intraperitoneal doxorubicin achieves access to mesenteric lymph nodes, case series of two patients. <i>International Journal of Surgery Case Reports</i> , 2019, 54, 108-112.	0.2	3
231	Acute abdomen caused by a large solitary jejunal diverticulum that induced a midgut volvulus. Report of a case. <i>International Journal of Surgery Case Reports</i> , 2020, 74, 109-112.	0.2	3
232	Splenic metastases – hematogenous disease or invasive peritoneal implants? Case reports of two patients. <i>International Journal of Surgery Case Reports</i> , 2020, 72, 266-270.	0.2	3
233	The Characteristics of 206 Long-Term Survivors with Peritoneal Metastases from Colorectal Cancer Treated with Curative Intent Surgery: A Multi-Center Cohort from PSOGI. <i>Cancers</i> , 2021, 13, 2964.	1.7	3
234	Laparoscopy technique in the setting of peritoneal metastases to avoid port site relapse. <i>Surgical Oncology</i> , 2021, 37, 101543.	0.8	3

#	ARTICLE	IF	CITATIONS
235	Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C. , 2002, 9, 186.		3
236	Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus. Annals of Surgical Oncology, 2015, 22, 2799.	0.7	3
237	Thin-walled cysts as a pathognomonic CT finding in cystic mesothelioma. Tumori, 2008, 94, 14-8.	0.6	3
238	Vertical abdominoplasty. Journal of Surgical Oncology, 2001, 78, 217-219.	0.8	2
239	Peritoneal metastases invading the seminal vesicles: Radiologic appearance and outcome of treatment. European Journal of Surgical Oncology, 2018, 44, 805-809.	0.5	2
240	A validated high performance liquid chromatography “ diode array detector method for the quantification of mitomycin C in plasma, peritoneal fluid and urine. Journal of Liquid Chromatography and Related Technologies, 2018, 41, 839-848.	0.5	2
241	Revised management of advanced primary colon cancer: Case series of 2 patients. International Journal of Surgery Case Reports, 2019, 55, 233-238.	0.2	2
242	Malignant peritoneal mesothelioma presenting as a mass in a Spigelian hernia. Report of a case. International Journal of Surgery Case Reports, 2020, 68, 239-241.	0.2	2
243	Ovarian cancer with peritoneal metastases has many treatment options and HIPEC is here to stay. Journal of Gastrointestinal Oncology, 2021, 12, S189-S190.	0.6	2
244	Adjuvant HIPEC for gastric cancer. Journal of Gastrointestinal Oncology, 2021, 12, S18-S19.	0.6	2
245	Intra-abdominal manifestations of pleural mesothelioma. Annals of Translational Medicine, 2017, 5, 231-231.	0.7	2
246	Peritoneal metastases from colorectal cancer in the absence of lymph node metastases show a high survival rate despite unfavorable prognostic indicators. European Journal of Surgical Oncology, 2022, 48, 1619-1625.	0.5	2
247	Protocols versus practice in the management of colorectal peritoneal metastases. Journal of Surgical Oncology, 2022, 125, 1200-1201.	0.8	2
248	Optimizing regional chemotherapy for epithelial ovarian cancer. Journal of Obstetrics and Gynaecology Research, 2022, , .	0.6	2
249	Biological considerations with pelvic neoplasms. , 2000, 73, 278-278.		1
250	Central venous access through the right gonadal vein. Journal of Surgical Oncology, 2002, 79, 71-71.	0.8	1
251	Getting Chemotherapy into the Cancerous Tissue. Annals of Surgical Oncology, 2008, 15, 3320-3320.	0.7	1
252	Optimization of Patient Selection for Surgical Approach to Peritoneal Metastases from Gastrointestinal Cancer Using Cytoreductive Surgery and Perioperative Chemotherapy. Current Colorectal Cancer Reports, 2014, 10, 272-278.	1.0	1

#	ARTICLE	IF	CITATIONS
253	A Patent Cranial End of the Ductus Venosus Can Result in Hemorrhage when Performing a Lesser Omentectomyâ€”Omental Bursectomy Procedure. <i>Annals of Surgical Oncology</i> , 2016, 23, 522-524.	0.7	1
254	Twenty-year survival of gastric cancer with peritoneal metastases using long-term normothermic intraperitoneal 5-fluorouracil and systemic mitomycin C: A case report. <i>International Journal of Surgery Case Reports</i> , 2019, 61, 302-304.	0.2	1
255	Rendezvous procedure to establish ureteral continuity from a delayed ureteral leak following pelvic surgery. A case report. <i>International Journal of Surgery Case Reports</i> , 2020, 76, 505-509.	0.2	1
256	Eliminating tumor cell entrapment from the natural history of ovarian cancer, a narrative summary. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2021, 42, 615.	0.3	1
257	Survival of large volume recurrent endometrial cancer with peritoneal metastases treated by cytoreductive surgery, HIPEC and EPIC. Report of a case. <i>International Journal of Surgery Case Reports</i> , 2021, 80, 105669.	0.2	1
258	PIPAC may work but more data is needed. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, S271-S272.	0.6	1
259	Intraperitoneal chemotherapy for peritoneal metastases: confronting diversity, maximizing benefit. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, S1-S4.	0.6	1
260	Rectovaginal fistula following low circular stapled anastomosis in women with rectal cancer. , 1996, 61, 155.		1
261	Extremity soft tissue sarcoma with metastases to abdominopelvic surfaces. , 1997, 64, 68.		1
262	Long-term survival in patients with peritoneal metastasized gastric cancer treated with cytoreductive surgery and HIPEC: A multi-institutional cohort from PSOGI.. <i>Journal of Clinical Oncology</i> , 2020, 38, 390-390.	0.8	1
263	The radiologist's role in the multidisciplinary team for patients with colon cancer peritoneal metastases. <i>Surgical Oncology</i> , 2022, 40, 101690.	0.8	1
264	Two methodologies of the rendezvous procedure to establish ureteral continuity from a delayed ureteral leak following pelvic surgery. <i>Surgical Oncology</i> , 2022, 40, 101697.	0.8	1
265	Is Repeated Hepatic Resection Justified for Malignancy?. <i>HPB Surgery</i> , 1991, 5, 66-70.	2.2	0
266	Liver Resection for Colorectal Secondaries. <i>HPB Surgery</i> , 1992, 6, 65-68.	2.2	0
267	Exteriorized small bowel as an abdomino-pelvic partition. <i>Journal of Surgical Oncology</i> , 2002, 80, 116-118.	0.8	0
268	Hybrid ileostomy. <i>Journal of Surgical Oncology</i> , 2006, 93, 161-163.	0.8	0
269	Peritonectomy for Peritoneal Carcinomatosis: Longâ€”Term Outcomes from a Single Brazilian Institution. <i>World Journal of Surgery</i> , 2009, 33, 840-840.	0.8	0
270	Reply to M. Markman. <i>Journal of Clinical Oncology</i> , 2010, 28, e419-e419.	0.8	0



#	ARTICLE	IF	CITATIONS
271	“Total Mesenteric Peritonectomy for Peritoneal Metastases” (with Video) by Jean-Baptiste Cazauran et al.. Annals of Surgical Oncology, 2017, 24, 3799-3800.	0.7	0
272	Management of malignancy-associated bowel obstruction by cervical esophagostomy and total parenteral nutrition, case series of 2 patients. International Journal of Surgery Case Reports, 2018, 53, 390-393.	0.2	0
273	Pseudomyxoma peritonei and appendiceal carcinoma with peritoneal metastases: current management strategies. Expert Opinion on Orphan Drugs, 2018, 6, 647-654.	0.5	0
274	Duodenectomy with jejunal advancement and reimplantation of the ampulla of Vater for recurrent right colon cancer: A case report. International Journal of Surgery Case Reports, 2019, 62, 1-4.	0.2	0
275	Observations on opening and closing the abdominal incision for cytoreductive surgery using a self-retaining retractor to reduce the incidence of incisional hernia. Surgical Oncology, 2020, 35, 5-11.	0.8	0
276	Management of patients with advanced ovarian cancer “ Role of complete cytoreduction and HIPEC: Attitudes of gynaecologist oncologists in two different continents. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2021, 61, E1-E2.	0.4	0
277	Knowledgeable case selection results in favorable outcomes. Journal of Gastrointestinal Oncology, 2021, 12, S30-S31.	0.6	0
278	Single institution best recommendation is HIPEC with cisplatin and docetaxel. Journal of Gastrointestinal Oncology, 2021, 12, S79-S79.	0.6	0
279	Aggressive local treatments may prolong survival but do not have curative intent. Journal of Gastrointestinal Oncology, 2021, 12, S68-S69.	0.6	0
280	Cashin and Graf: long-term intraperitoneal 5-fluorouracil is superior to adjuvant FOLFOX in a randomized trial. Journal of Gastrointestinal Oncology, 2021, 12, S136-S136.	0.6	0
281	Peritoneal progression after pancreaticoduodenectomy is a devastating surgical treatment failure: HIPEC gemcitabine is an option. Journal of Gastrointestinal Oncology, 2021, 12, S118-S119.	0.6	0
282	Current data is sufficient to recommend a current standard of care. Journal of Gastrointestinal Oncology, 2021, 12, S45-S46.	0.6	0
283	The options are neoadjuvant, adjuvant, or no chemotherapy at all: further data is needed. Journal of Gastrointestinal Oncology, 2021, 12, S214-S215.	0.6	0
284	Super-responders to bidirectional neoadjuvant chemotherapy showed prolonged survival. Journal of Gastrointestinal Oncology, 2021, 12, S57-S58.	0.6	0
285	Genetic targets for cancer control are a reality. Journal of Gastrointestinal Oncology, 2021, 12, S204-S205.	0.6	0
286	ASO Author Reflections: Normothermic Intraperitoneal Chemotherapy Long-Term for Malignant Peritoneal Mesothelioma. Annals of Surgical Oncology, 2021, 28, 7118-7119.	0.7	0
287	Paclitaxel is the pharmacologic near perfect chemotherapy for peritoneal metastases. Journal of Gastrointestinal Oncology, 2021, 12, S240-S241.	0.6	0
288	A model for accurate histopathologic assessment refines treatment options. Journal of Gastrointestinal Oncology, 2021, 12, S230-S230.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Peritonectomy of the colonic mesentery. Case report of a new surgical technology. International Journal of Surgery Case Reports, 2021, 86, 106369.	0.2	0
290	Nomograms to predict prognosis in pseudomyxoma peritonei: A Peritoneal Surface Oncology Group International (PSOGI) multicenter study.. Journal of Clinical Oncology, 2014, 32, 4033-4033.	0.8	0
291	Peritoneal Surface Oncology Group International (PSOGI) multicenter study on nomograms to predict overall survival in diffuse malignant peritoneal mesothelioma.. Journal of Clinical Oncology, 2018, 36, e15701-e15701.	0.8	0
292	Cytoreductive Surgery for Advanced Colon Cancer. Turkish Journal of Colorectal Disease, 2020, 30, 9-16.	0.2	0
293	Development of drug resistance in colon cancer patients following chemotherapy, a contributing factor in the failure of oxaliplatin-based HIPEC to improve survival in the Prodigé 7 trial.. Journal of Clinical Oncology, 2020, 38, 4063-4063.	0.8	0
294	Chemoresistance can limit the success of radical surgery followed by early postoperative intraperitoneal chemotherapy in gastric carcinoma (reply). , 2000, 2, 322-324.		0
295	Progression of perforated cystadenoma of the appendix to pseudomyxoma peritonei over 18Âyears. A case report. International Journal of Surgery Case Reports, 2022, 91, 106756.	0.2	0
296	Visceral and retroperitoneal sarcomas: clinical presentation and therapeutic options. , 2003, 5, 298-302.		0